Alnylam reports preliminary 2025 net product revs $2,987M (+81% YoY); guides 2026 revs $4.9B-$5.3B

ALNYLAM PHARMACEUTICALS, INC.

2025-FY EPS reported $2.33 revenue$3,713,937,000

Preliminary 2025 net product revenue $2,987M (81% growth vs 2024); TTR franchise $2,487M (103% growth).
2026 combined net product revenue guidance $4.9B–$5.3B (71% growth at midpoint); TTR guidance $4.4B–$4.7B.
New 'Alnylam 2030' strategy targets 25%+ total revenue CAGR and ~30% non-GAAP operating margin by 2030.
Pipeline goals: nucresiran Phase 3 in ATTR-CM/polyneuropathy; mivelsiran Phase 2 enrollment in H1 2026.
Preliminary Q4 2025: total TTR revs ~$859M (AMVUTTRA $827M, ONPATTRO $32M); total rare revs ~$137M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.